<i>Mycoplasma genitalium,</i> an agent of reemerging sexually transmitted infections

Edouard, Sophie; Tissot‐Dupont, Hervé; Dubourg, Grégory; Bernard, Annick; Fournier, Pierre‐Edouard; Ravaux, Isabelle; Stein, Andréas; Raoult, Didier

doi:10.1111/apm.12731

Cited by 8 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,13 Nevertheless, a number of prevalence studies worldwide have identified significant rates in both men and women. 6,13,26–28 In the present study, the MG rate among women was 4.2%. Other Brazilian studies have reported rates from 0.9 to 28.1%.…”

Section: Discussionsupporting

confidence: 47%

Prevalence and risk factors associated with Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium among women in Pelotas, Southern Brazil

et al. 2020

View full text Add to dashboard Cite

The frequently asymptomatic sexually transmitted infections (STIs) caused by Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Mycoplasma genitalium (MG) are poorly diagnosed in Brazil and can lead to severe complications/sequelae without timely detection and treatment. We investigated prevalence of CT, NG, and MG infections and associated demographic, behavioral, and clinical factors in consecutive women attending a gynecology and obstetrics outpatient clinic in Pelotas, Southern Brazil. Vaginal swab samples were prospectively obtained from asymptomatic and symptomatic women (n = 498) from August 2015 to December 2016 and tested with Aptima Combo2 and Aptima M. genitalium assays (Hologic). The prevalence of CT, NG, and MG was 6.8% (34/498), 1.0% (5/498), and 4.2% (21/498), respectively. Three (0.6%) cases of CT and NG co-infection and one (0.2%) case of CT and MG co-infection were identified. The risk factors associated with these bacterial STIs were youth (<30 years), no steady sexual partner, infection with additional STI, and lack of income. Bacterial STIs, particularly CT and MG, were prevalent among women, including pregnant women (60% of positive cases), in Pelotas, Brazil. Sensitive and specific diagnostic testing and early treatment are essential to control STIs, limit transmission chains, avoid future complications/sequelae, and reduce health and cost burdens on the population.

show abstract

Section: Discussionsupporting

confidence: 47%

Prevalence and risk factors associated with Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium among women in Pelotas, Southern Brazil

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The WHO has no global infection estimates and M. genitalium infection is not mandatory reported internationally (2,4). Nevertheless, numerous prevalence studies worldwide have identified rates between 1.3% and 3.9% in the general population (20)(21)(22). In the present study, prevalence of M. genitalium infection was 2.49%.…”

Section: Disscussionmentioning

confidence: 42%

Prevalence of Neisseria Gonorrhoeae and Mycoplasma Genitalium in Bulgarian Population From Sofia Municipality of Reproductive Age, 2018-2019

Levterova¹,

Simeonovski²,

Ivanova³

et al. 2021

Probl Infect Parasit Dis

View full text Add to dashboard Cite

Background: N. gonorrhoeae and M. genitalium infections remain public health concern due to emerging antimicrobial resistance which compromise effective treatment and infection prevention and control. Objective: To estimate the prevalence for N. gonorrhoeae and M. genitalium infections and identify demographic and sexual behavioral risk factors in Bulgarian population of reproductive age from Sofia municipality. Material and methods: Participants were sexually active 443 men and 198 women aged 18-49 years. They answered questionnaires on sexual behavior and provided samples for N. gonorrhoeae and M. genitalium testing. Results: The prevalence of N. gonorrhoeae infection was 3.28% (21/641) and with M. genitalium infection it was 2.49% (16/641). For both infections the presence of urogenital symptoms was associated with greater risk of being infected. Among gonococcal infections an increased number of lifetime partners and partners during the last 6 months, previously diagnosed STIs and use of contraception other than condoms were associated risk factors. Conclusions: The prevalence of N. gonorrhoeae and M. genitalium infections in Bulgarian population of reproductive age from Sofia municipality was relatively low but due to significant disease burden data on prevalence and identified risk factors should help the development of future control strategies.

show abstract

“…Mycoplasma genitalium has successfully established itself as a relatively new sexually transmitted infectious (STI) agent that has devastating health effects on men and women alike [ 1 ]. The increasing prevalence of multidrug-resistant M. genitalium has made it the most common cause of STI, second to Chlamydia trachomatis [ 2 ]. A CDC report has recently put this bacteria on the “watch list” of antibiotic resistance threats, due to its rapid development of resistance to many antibiotics, including macrolides and fluoroquinolones used for treating other STIs [ 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

Vaccinomics-Aided Development of a Next-Generation Chimeric Vaccine against an Emerging Threat: Mycoplasma genitalium

et al. 2022

View full text Add to dashboard Cite

Mycoplasma genitalium, besides urethritis, causes a number of other sexually transmitted diseases, posing a significant health threat to both men and women, particularly in developing countries. In light of the rapid appearance of multidrug-resistant strains, M. genitalium is regarded as an emerging threat and has been placed on the CDC’s “watch list”. Hence, a protective vaccine is essential for combating this pathogen. In this study, we utilized reverse vaccinology to develop a chimeric vaccine against M. genitalium by identifying vaccine targets from the reference proteome (Strain G-37) of this pathogen. A multiepitope vaccine was developed using proteins that are non-toxic, non-allergic, and non-homologous to human proteins. Several bioinformatic tools identified linear and non-linear B-cell epitopes, as well as MHC epitopes belonging to classes I and II, from the putative vaccine target proteins. The epitopes that showed promiscuity among the various servers were shortlisted and subsequently selected for further investigation based on an immunoinformatic analysis. Using GPGPG, AAY, and KK linkers, the shortlisted epitope sequences were assembled to create a chimeric construct. A GPI anchor protein immunomodulating adjuvant was adjoined to the vaccine construct’s N-terminus through the EAAK linker so as to improve the overall immunogenicity. For further investigations of the designed construct, various bioinformatic tools were employed to study the physicochemical properties, immune profile, solubility, and allergenicity profile. A tertiary chimeric design was computationally modeled using I-TASSER and Robetta and was subsequently refined through GalaxyRefine. ProSA-Web was exploited to corroborate the quality of the construct by detecting errors and the Ramachandran plot was used to identify possible quality issues. Simulation studies of the molecular dynamics demonstrated the robustness and flexibility of the designed construct. Following the successful docking of the designed model to the immune receptors, the construct was computationally cloned into Escherichia coli plasmids to affirm the efficient expression of the designed construct in a biological system.

show abstract

Mycoplasma genitalium, an agent of reemerging sexually transmitted infections

Cited by 8 publications

References 23 publications

Prevalence and risk factors associated with Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium among women in Pelotas, Southern Brazil

Prevalence and risk factors associated with Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium among women in Pelotas, Southern Brazil

Prevalence of Neisseria Gonorrhoeae and Mycoplasma Genitalium in Bulgarian Population From Sofia Municipality of Reproductive Age, 2018-2019

Vaccinomics-Aided Development of a Next-Generation Chimeric Vaccine against an Emerging Threat: Mycoplasma genitalium

Contact Info

Product

Resources

About